Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a research-grade, selective agonist for hydroxycarboxylic acid receptors HM74A/GPR109A and GPR109B, crucial for lipid metabolism regulation (Ye et al., 2025). Its molecular structure and binding modes have been validated by cryo-EM and deposited in public databases. Acifran demonstrates high purity (98.00%) and is suitable for precise activation of target G-protein coupled receptors in metabolic disorder research (APExBIO). It exhibits solubility of <21.82 mg/ml in ethanol or DMSO and is stable at -20°C when shipped with blue ice. Acifran’s specificity, structural clarity, and workflow integration capabilities distinguish it from less-targeted hypolipidemic agents (contrast: INCB018424 article).

Biological Rationale

Lipid metabolism is tightly regulated by specific G-protein coupled receptors (GPCRs), including the hydroxycarboxylic acid receptor subtypes HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) (Ye et al., 2025). These receptors act as metabolite sensors and are prominent targets for addressing dyslipidemia and related metabolic disorders. Acifran directly and selectively engages these GPCRs, providing a robust tool for dissecting lipid signaling pathways. Structural studies validate the ligand-receptor interactions, enabling rational experimental design for metabolic disorder models. This compound’s role is distinct from broad-spectrum lipid modulators, as it offers targeted receptor engagement, reducing off-target effects and increasing reproducibility (contrast: Entinostat.net article).

Mechanism of Action of Acifran

Acifran selectively activates the HM74A/GPR109A and GPR109B receptors, both part of the hydroxycarboxylic acid receptor family. Upon binding, Acifran induces conformational changes in these GPCRs, coupling them to Gi proteins and initiating downstream signaling cascades that regulate lipid metabolism (Ye et al., 2025). Cryo-EM structures reveal that Acifran binds in the orthosteric pocket, interacting with key residues such as F1073.32 in HCAR3. This interaction is critical for ligand selectivity and receptor activation. The compound’s mode of action avoids the cutaneous flushing associated with HCAR2 activation by other agonists, making it a preferred probe for mechanistic studies.

Evidence & Benchmarks

• Acifran binds HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) with high selectivity, as demonstrated by cryo-EM at 2.72–3.18 Å resolution (Ye et al., 2025).
• Atomic coordinates of Acifran-receptor complexes are publicly available under PDB codes 9JKX (HCAR3) and 9JKY (HCAR2) (DOI).
• Acifran shows a molecular weight of 218.21 Da and chemical formula C₁₂H₁₀O₄, with <21.82 mg/ml solubility in ethanol and DMSO (APExBIO).
• Functional assays in HEK-293 cells confirm selective Gi-coupled receptor activation, with minimal off-target signaling (Ye et al., 2025).
• No significant degradation of Acifran was observed at -20°C over standard laboratory timeframes, ensuring experimental reproducibility (APExBIO).

Applications, Limits & Misconceptions

Acifran’s verified selectivity and structural characterization make it a benchmark tool for metabolic disorder research. Its applications include:

• Dissection of lipid signaling pathways in cellular and molecular models.
• Structural studies of GPCR activation and ligand specificity (see: Acifran as a Structural Probe—this article extends prior analyses by detailing cryo-EM validated interactions).
• Development of next-generation hypolipidemic strategies with minimized adverse effects.
• Validation of receptor-ligand interactions in translational lipid metabolism research (compare: INCB018424.com article—this article clarifies the mechanistic basis for selectivity and workflow recommendations).

Common Pitfalls or Misconceptions

• Acifran is not intended or validated for diagnostic or therapeutic use in humans (APExBIO).
• Solutions of Acifran are not recommended for long-term storage; activity decreases with prolonged solution phase exposure at ambient temperature.
• Acifran’s selectivity is limited to HM74A/GPR109A and GPR109B; it is not a pan-GPCR agonist.
• May not fully recapitulate in vivo lipid metabolism dynamics due to system complexity—cellular context is critical.
• High concentrations above solubility limits (>21.82 mg/ml in ethanol/DMSO) may result in precipitation and loss of activity.

Workflow Integration & Parameters

Acifran (SKU: B6848) is supplied as an off-white solid with 98.00% purity by APExBIO (product page). For experimental use, dissolve in ethanol or DMSO to a maximum of 21.82 mg/ml. Store aliquots at -20°C; avoid repeated freeze-thaw cycles. Shipments are made with blue ice to maintain stability. Use solutions promptly after preparation to ensure activity. For receptor activation assays, titrate concentration based on cell model and receptor expression levels. Refer to published cryo-EM structures (PDB 9JKX/9JKY) for rational ligand design and control experiments. This article extends best-practice guidance found in entinostat.net by providing updated solubility and storage data, as well as verified receptor selectivity parameters.

Conclusion & Outlook

Acifran is a rigorously characterized HM74A/GPR109A and GPR109B agonist, offering precise, reproducible modulation of lipid signaling pathways in research settings. Its high purity, structural validation, and defined selectivity make it a gold-standard tool for metabolic disorder research and GPCR mechanistic studies. As structural biology continues to advance, Acifran will remain integral for benchmarking new agonists and optimizing translational workflows. For further technical details or to order, visit the Acifran product page at APExBIO.